Literature DB >> 23322460

Symptoms related to tumor necrosis factor receptor 1-associated periodic syndrome, multiple sclerosis, and severe rheumatoid arthritis in patients carrying the TNF receptor superfamily 1A D12E/p.Asp41Glu mutation.

Joachim Havla1, Peter Lohse, Lisa Ann Gerdes, Reinhard Hohlfeld, Tania Kümpfel.   

Abstract

OBJECTIVE: Tumor necrosis factor (TNF) receptor 1-associated periodic syndrome (TRAPS) is an autoinflammatory disorder caused by autosomal dominantly inherited mutations in the TNF receptor superfamily 1A (TNFRSF1A) gene. The D12E substitution has been described only once to date, in a 4-year-old boy with fever.
METHODS: For DNA sequence analysis of the TNFRSF1A gene, genomic DNA was isolated, amplified by PCR, purified, and sequenced.
RESULTS: We describe 3 families (8 subjects) with the TNFRSF1A D12E substitution and TRAPS-related symptoms, in 4 cases associated with the autoimmune diseases multiple sclerosis and rheumatoid arthritis.
CONCLUSION: The clinical phenotype might be associated with the TNFRSF1A D12E mutation. There is a close pathophysiological relationship between TNF signaling and autoimmune disorders.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23322460     DOI: 10.3899/jrheum.120729

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  3 in total

Review 1.  Tumor necrosis factor-associated periodic syndrome in adults.

Authors:  Sharika Gopakumar Menon; Petros Efthimiou
Journal:  Rheumatol Int       Date:  2017-09-23       Impact factor: 2.631

2.  Neurological phenotypes in patients with NLRP3-, MEFV-, and TNFRSF1A low-penetrance variants.

Authors:  Elisabeth Mulazzani; Danny Wagner; Joachim Havla; Miriam Schlüter; Ingrid Meinl; Lisa-Ann Gerdes; Tania Kümpfel
Journal:  J Neuroinflammation       Date:  2020-06-20       Impact factor: 8.322

3.  A Pro-Inflammatory Signature Constitutively Activated in Monogenic Autoinflammatory Diseases.

Authors:  Paola Galozzi; Ola Negm; Sara Bindoli; Patrick Tighe; Paolo Sfriso; Leonardo Punzi
Journal:  Int J Mol Sci       Date:  2022-02-05       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.